Income Statement (Annual)

KMR / Kinder Morgan, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Adminstrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.

All numbers are times 1,000 except per share units.

2009 2010 2011 2012 2013 2014 2015 2016 2017
Net Income Loss
  Profit Loss 773,100 300,000 660,000 427,000 2,692,000 2,443,000 208,000 721,000 223,000
Other Comprehensive Income Loss Net Of Tax Period Increase Decrease
  Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax -347,500 -53,400 12,700 -4,000 -38,000 409,000 164,000 -104,000 145,000
  Other Comprehensive Income Loss Reclassification Adjustment From A O C I On Derivatives Net Of Tax - - -184,000 8,000 -11,000 25,000 272,000 116,000 171,000
  Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax - - -35,000 32,000 -103,000 -138,000 -214,000 34,000 101,000
  Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax - - 61,000 35,000 -170,000 226,000 122,000 14,000 -40,000
  Other Comprehensive Income Loss Net Of Tax - - 108,000 71,000 40,000 20,000 -444,000 -200,000 115,000
  Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest 609,300 426,700 769,700 498,000 2,732,000 2,463,000 -236,000 521,000 338,000
  Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest 228,800 436,600 153,400 186,000 1,445,000 1,486,000 -45,000 13,000 86,000
  Comprehensive Income Net Of Tax 380,500 -9,900 616,300 312,000 1,287,000 977,000 -191,000 508,000 252,000

Peers - Natural Gas Transmission (4922)

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

CUSIP: 49455U100